Year: 2025
Type: article
Abstract: Narayan et al. 1 described the development of an in silico platform (“Drug Atlas”) to predict synergistic drug combinations and claimed successful in vivo validation in five models. Demonstrating the impact of a given drug in in vivo models is challenging because effect sizes are often small 2 . Because of the inherent variability in tumor outgrowth in vivo, achieving adequate statistical power requires sufficiently sized groups. As the experimental complexity increases, for example, when assessing combination effects, the minimum required group size also increases. A statistically sound distinction between additive and synergistic drug effects requires even larger datasets, as do comparisons across multiple drug combinations of drugs.
Source: Nature Communications
Authors: Olaf van Tellingen, Renee X. de Menezes
Institution: The Netherlands Cancer Institute
Language: English
Subfield: Drug Discovery
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W4414670356
